APA

Panaccione R., Colombel J., Sandborn W. J., Rutgeerts P., D'Haens G. R., Robinson A. M., Chao J., Mulani P. M. & Pollack P. F. (20110105). Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. : Alimentary pharmacology & therapeutics.

Chicago

Panaccione R, Colombel J-F, Sandborn W J, Rutgeerts P, D'Haens G R, Robinson A M, Chao J, Mulani P M and Pollack P F. 20110105. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. : Alimentary pharmacology & therapeutics.

Harvard

Panaccione R., Colombel J., Sandborn W. J., Rutgeerts P., D'Haens G. R., Robinson A. M., Chao J., Mulani P. M. and Pollack P. F. (20110105). Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. : Alimentary pharmacology & therapeutics.

MLA

Panaccione R, Colombel J-F, Sandborn W J, Rutgeerts P, D'Haens G R, Robinson A M, Chao J, Mulani P M and Pollack P F. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. : Alimentary pharmacology & therapeutics. 20110105.